CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 21737585.
- Also identified by DOI 10.1164/rccm.201105-0827WS and PMC identifier 3208659.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. The goals were to assess recent surrogate marker research and to provide specific recommendations for (1) the qualification and validation of biomarkers of treatment outcome; (2) the standardization of specimen and data collection for future clinical trials, including a minimum set of samples and collection time points; and (3) the creation ofa specimen repository to support biomarker testing. This article summarizes these recommendations and provides a roadmap for their implementation.
Medical subject headings
- Biomarkers
- Clinical Trials as Topic
- Specimen Handling
- Tuberculosis